<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MEASLES, MUMPS AND RUBELLA VACCINE, LIVE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MEASLES, MUMPS AND RUBELLA VACCINE, LIVE</h1>

        <p><a href="../drugClass/PHP34568.html">VACCINES</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Primary immunisation against measles, mumps, and rubella (first dose)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by deep subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 12&#8211;13 months</strong><br/>
                0.5 mL for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Primary immunisation against measles, mumps, and rubella (second dose)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by deep subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 40 months&#8211;5 years</strong><br/>
                0.5 mL for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Rubella immunisation (in seronegative women, susceptible to rubella and in unimmunised, seronegative women, post-partum)</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by deep subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults females of childbearing potential</strong><br/>
                (consult product literature or local protocols).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Children presenting for pre-school booster, who have not received the primary immunisation (first dose)</span>,
                <span class="indication">Immunisation for patients at school-leaving age or at entry into further education, who have not completed the primary immunisation course</span>,
                <span class="indication">Control of measles outbreak</span>,
                <span class="indication">Immunisation for patients travelling to areas where measles is endemic or epidemic, who have not completed the primary immunisation</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by deep subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature or local protocols).</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years</strong><br/>
                (consult product literature or local protocols).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>







      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>uncommon:</strong> Parotid swelling (usually in the third week), sleep disturbances, unusual crying in infants,
              </p>
              <p>
                <strong>rare:</strong> Arthropathy (2 to 3 weeks after immunisation), idiopathic thrombocytopenic purpura,
              </p>
              <p>
                <strong>notKnown:</strong> Optic neuritis, peripheral neuritis,
              </p>
        
        
            <section class="advice">
              <p>Malaise, fever, or a rash can occur after the first dose of MMR vaccine&#8211;most commonly about a week after vaccination and lasting about 2 to 3 days. Leaflets are available for parents on advice for reducing fever (including the use of paracetamol).</p><p>Febrile seizures&#8211;occur rarely 6 to 11 days after MMR vaccination (the incidence is lower than that following measles infection)</p>
            </section>
            <section class="advice">
                <h3>Idiopathic thrombocytopenic purpura</h3>
              <p>Idiopathic thrombocytopenic purpura has occurred rarely following MMR vaccination, usually within 6 weeks of the first dose. The risk of idiopathic thrombocytopenic purpura after MMR vaccine is much less than the risk after infection with wild measles or rubella virus. Children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR should undergo serological testing before the second dose is due; if the results suggest incomplete immunity against measles, mumps or rubella then a second dose of MMR is recommended. The Specialist and Reference Microbiology Division, Health Protection Agency offers free serological testing for children who develop idiopathic thrombocytopenic purpura <i>within 6 weeks</i> of the first dose of MMR.</p>
            </section>
            <section class="advice">
                <h3>Aseptic meningitis</h3>
              <p>Post-vaccination aseptic meningitis was reported (rarely and with complete recovery) following vaccination with MMR vaccine containing Urabe mumps vaccine, which has now been discontinued; no cases have been confirmed in association with the currently used Jeryl Lynn mumps vaccine. Children with post-vaccination symptoms are not infectious.</p>
            </section>
            <section class="advice">
                <h3>Frequency of side effects</h3>
              <p>Adverse reactions are considerably less frequent after the second dose of MMR vaccine than after the first.</p>
            </section>
        
      </section>




      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MMR vaccination and bowel disease or autism</h3>
              <p>Reviews undertaken on behalf of the CSM, the Medical Research Council, and the Cochrane Collaboration, have not found any evidence of a link between MMR vaccination and bowel disease or autism. The Chief Medical Officers have advised that the MMR vaccine is the safest and best way to protect children against measles, mumps, and rubella. Information (including fact sheets and a list of references) may be obtained from<xref format="html" href="http://www.dh.gov.uk/immunisation">www.dh.gov.uk/immunisation</xref>.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Antibody response to measles component may be reduced after immunoglobulin administration or blood transfusion&#8211;leave an interval of at least 3 months before MMR immunisation
          </li>
        </ul>
        <ul>
          <li>
            <p>MMR vaccine should not be administered on the same day as yellow fever vaccine; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.</p><p>MMR and varicella-zoster vaccine can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before immunisation.</p><p>Avoid pregnancy for at least 1 month after vaccination.</p>
            </section>
      </section>


      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 9 months.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Available as part of childhood immunisation schedule from health organisations or ImmForm<xref format="html" href="http://www.immform.dh.gov.uk">www.immform.dh.gov.uk</xref>.</p>
            </section>
      </section>








      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>MMR vaccine can be given safely even when the child has had an anaphylactic reaction to food containing egg. Dislike of eggs, refusal to eat egg, or confirmed anaphylactic reactions to egg-containing food is not a contra-indication to MMR vaccination. Children with a confirmed anaphylactic reaction to the MMR vaccine should be assessed by a specialist.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MEASLES, MUMPS AND RUBELLA VACCINE, LIVE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP74756"><a href="../medicinalForm/PHP74756.html" data-target="#PHP74756" data-action="load">Powder and solvent for solution for injection</a></div>
            <div id="PHP74763"><a href="../medicinalForm/PHP74763.html" data-target="#PHP74763" data-action="load">Powder and solvent for suspension for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
